Angiogenic Aptamer-Modified Tetrahedral Framework Nucleic Acid Promotes Angiogenesis In Vitro and In Vivo
Source abstract
Abstract
In a search for a solution to large-area soft and hard tissue defects, whether or not tissue regeneration or tissue-substitutes transplantation is used, the problems with angiogenesis need to be solved urgently. Thus, a new and efficient proangiogenic approach is needed. Nanoengineering systems have been considered one of the most promising approaches. In this study, we modify the tetrahedral framework nucleic acid (tFNA) for the first time with two different angiogenic DNA aptamers to form aptamer-tFNA nanostructures, tFNA-Apt02 and tFNA-AptVEGF, and the effects of them on angiogenesis both in vitro and in vivo are investigated. We develop new nanomaterials for enhancing angiogenesis to solve the problem of tissue engineering vascularization and ischemic diseases. The results of our study confirm that tFNA-Apt02 and tFNA-AptVEGF has a stronger ability to accelerate endothelial cell proliferation and migration, tubule formation, spheroid sprouting, and angiogenesis in vivo. We first demonstrate that the engineered novel tFNA-Apt02 and tFNA-AptVEGF have promoting effects on angiogenesis both in vitro and in vivo and provide a theoretical basis and opportunity for their application in tissues engineering vascularization and ischemic diseases.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: Advanced biosensing and bioanalysis techniques · RNA Interference and Gene Delivery · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
State Key Laboratory of Oral Diseases, National Clinical Research Center for Oral Diseases, Department of Oral & Maxillofacial Surgery, West China Hospital of Stomatology, Sichuan University, Chengdu 610041, P.R. China
Department of Oral and Maxillofacial Surgery, The Affiliated Stomatology Hospital of Southwest Medical University, Luzhou 646000, P.R. China
Funding
National Natural Science Foundation of China · National Key R&D Program of China
References (48)
Show source-provided references
1. 10.1007/s11914-019-00519-910.1007/s11914-019-00519-9 ↗
2. 10.3390/ijms2205247210.3390/ijms22052472 ↗
3. 10.1016/S0169-409X(98)00025-810.1016/S0169-409X(98)00025-8 ↗
4. 10.3390/ijms1912410210.3390/ijms19124102 ↗
5. 10.1016/j.bioactmat.2021.02.03610.1016/j.bioactmat.2021.02.036 ↗
6. 10.1063/5.004402710.1063/5.0044027 ↗
7. Zarem H. A. · Surgery · 1969 · 66 · 392
8. 10.1002/mabi.20090010710.1002/mabi.200900107 ↗
9. 10.4172/2161-0444.100024710.4172/2161-0444.1000247 ↗
10. 10.1002/adfm.20200734210.1002/adfm.202007342 ↗
11. 10.1001/jama.1993.0350015007903110.1001/jama.1993.03500150079031 ↗
12. 10.1088/0957-4484/25/7/07560210.1088/0957-4484/25/7/075602 ↗
13. 10.1007/s40242-019-9249-410.1007/s40242-019-9249-4 ↗
14. 10.1021/jacs.8b1052910.1021/jacs.8b10529 ↗
15. 10.1007/s40820-021-00614-610.1007/s40820-021-00614-6 ↗
16. 10.1016/j.cej.2020.12742610.1016/j.cej.2020.127426 ↗
17. 10.1016/j.bioactmat.2020.12.02710.1016/j.bioactmat.2020.12.027 ↗
18. 10.1038/s41596-020-0355-z10.1038/s41596-020-0355-z ↗
19. 10.1021/acs.nanolett.0c0052910.1021/acs.nanolett.0c00529 ↗
20. 10.1002/adma.20210094910.1002/adma.202100949 ↗
21. 10.1021/acsami.8b1651810.1021/acsami.8b16518 ↗
22. 10.1021/acsami.0c0087410.1021/acsami.0c00874 ↗
23. 10.1021/acsami.0c1383910.1021/acsami.0c13839 ↗
24. 10.1038/346818a010.1038/346818a0 ↗
25. 10.1016/j.talanta.2021.12218810.1016/j.talanta.2021.122188 ↗
26. 10.1021/acsami.0c0575010.1021/acsami.0c05750 ↗
27. 10.3390/life1103019310.3390/life11030193 ↗
28. 10.3390/s2103073610.3390/s21030736 ↗
29. 10.1146/annurev-pharmtox-010716-10455810.1146/annurev-pharmtox-010716-104558 ↗
30. 10.1089/nat.2020.087510.1089/nat.2020.0875 ↗
31. 10.1002/med.2173710.1002/med.21737 ↗
32. 10.1111/j.1582-4934.2005.tb00379.x10.1111/j.1582-4934.2005.tb00379.x ↗
33. 10.1016/j.cell.2011.08.03910.1016/j.cell.2011.08.039 ↗
34. 10.1161/CIRCRESAHA.116.31053510.1161/CIRCRESAHA.116.310535 ↗
35. 10.1016/j.omtn.2019.12.03410.1016/j.omtn.2019.12.034 ↗
36. 10.1021/ac303023d10.1021/ac303023d ↗
37. 10.1016/j.actbio.2019.08.04710.1016/j.actbio.2019.08.047 ↗
38. 10.1039/c3lc41320a10.1039/c3lc41320a ↗
39. 10.1021/acsami.7b1096010.1021/acsami.7b10960 ↗
40. 10.1007/s10456-018-9613-x10.1007/s10456-018-9613-x ↗
41. 10.1016/S0021-9258(19)49853-010.1016/S0021-9258(19)49853-0 ↗
42. 10.1038/7465110.1038/74651 ↗
43. 10.1021/acs.nanolett.9b0132010.1021/acs.nanolett.9b01320 ↗
44. 10.2147/NSA.S22719310.2147/NSA.S227193 ↗
45. 10.1021/acsnano.8b0632210.1021/acsnano.8b06322 ↗
46. 10.1039/C8NR02411A10.1039/C8NR02411A ↗
47. 10.1002/adfm.20210143510.1002/adfm.202101435 ↗
48. 10.1016/j.biomaterials.2014.04.11210.1016/j.biomaterials.2014.04.112 ↗